No clinical evidence was identified for the NRT products specifically termed as Nicorette Quick Mist, Nicorette Combo Quit or Nicorette Mini Lozenges. However, limited evidence showed that nicotine mouth spray or the combination of nicotine patch plus gum achieved higher smoking cessation than placebo. No statistically significant difference were found between nicotine Lozenge 2mg or 4mg) with nicotine patch. Statistically significant higher smoking cessation rates, despite the modest effect size, were observed with high dose nicotine patches (>22mg) compared with standard dose nicotine patch use (<22mg). NRT appears effective in the smoking reduction for those smokers who did not want to quit, failed from previous NRT, or intended to quit smoking gradually. No statistically significant different adverse events were identified among various NRT products. However, due to the methodological limitations and clinical heterogeneity of the body evidence, the findings identified in this review should be interpreted with caution. Better designed RCTs in Canadian settings are needed to determine the clinical effectiveness of the newer NRT products (Nicorette Quick Mist, Nicorette Combo Quit, Nicorette Mini Lozenges) or the use of supratherapeutic doses of nicotine for smoking cessation, and NRT’s role in the smoking reduction for those who do not intend to quit.